nifedipine	tolbutamide	65	63	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	none	none	none
nifedipine	tolbutamide	63	63	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	none	none	none
nifedipine	tolbutamide	62	63	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	none	none	none
nifedipine	Hydrochlorothiazide	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	5487	none	D006852
nifedipine	Hydrochlorothiazide	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	5487	none	D006852
nifedipine	Hydrochlorothiazide	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	5487	none	D006852
nifedipine	Hydrochlorothiazide	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	5487	none	D006852
nifedipine	Hydrochlorothiazide	65	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	5487	none	D006852
nifedipine	Hydrochlorothiazide	65	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	5487	none	D006852
nifedipine	Hydrochlorothiazide	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	5487	none	D006852
nifedipine	Hydrochlorothiazide	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	5487	none	D006852
nifedipine	Hydrochlorothiazide	63	65	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	5487	none	D006852
nifedipine	Hydrochlorothiazide	63	65	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	5487	none	D006852
nifedipine	Hydrochlorothiazide	63	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	5487	none	D006852
nifedipine	Hydrochlorothiazide	63	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	5487	none	D006852
nifedipine	Hydrochlorothiazide	62	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	5487	none	D006852
nifedipine	Hydrochlorothiazide	62	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	5487	none	D006852
nifedipine	Irbesartan	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	83818	none	83818
nifedipine	Irbesartan	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	83818	none	83818
nifedipine	Irbesartan	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	83818	none	83818
nifedipine	Irbesartan	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	83818	none	83818
nifedipine	Irbesartan	65	64	true	negative	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
nifedipine	Irbesartan	65	64	true	negative	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
nifedipine	Irbesartan	65	65	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
nifedipine	Irbesartan	65	65	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
nifedipine	Irbesartan	65	67	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	83818	none	83818
nifedipine	Irbesartan	65	67	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	83818	none	83818
nifedipine	Irbesartan	65	63	true	negative	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
nifedipine	Irbesartan	65	63	true	negative	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
nifedipine	Irbesartan	63	64	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	83818	none	83818
nifedipine	Irbesartan	63	64	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	83818	none	83818
nifedipine	Irbesartan	63	65	true	negative	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
nifedipine	Irbesartan	63	65	true	negative	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
nifedipine	Irbesartan	63	63	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	83818	none	83818
nifedipine	Irbesartan	63	63	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	83818	none	83818
nifedipine	Irbesartan	62	64	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	83818	none	83818
nifedipine	Irbesartan	62	64	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	83818	none	83818
nifedipine	Irbesartan	62	63	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	83818	none	83818
nifedipine	Irbesartan	62	63	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	83818	none	83818
nifedipine	Irbesartan	62	60	true	negative	Hepatic Insufficiency    The pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver.  No dosage adjustment is necessary in patients with hepatic insufficiency.  Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	83818	none	83818
nifedipine	Irbesartan	62	60	true	negative	Hepatic Insufficiency    The pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver.  No dosage adjustment is necessary in patients with hepatic insufficiency.  Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	83818	none	83818
nifedipine	warfarin	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	none	none	none
nifedipine	warfarin	65	64	false	none	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	none	none	none
nifedipine	warfarin	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	none	none	none
nifedipine	warfarin	63	64	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	none	none	none
nifedipine	warfarin	63	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	none	none	none
nifedipine	warfarin	62	64	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	none	none	none
nifedipine	warfarin	62	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	none	none	none
nifedipine	prothrombin	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	none	none	none
nifedipine	prothrombin	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	none	none	none
nifedipine	thiazide	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	none	none	none
nifedipine	thiazide	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	none	none	none
nifedipine	thiazide	65	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	none	none	none
nifedipine	thiazide	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	none	none	none
nifedipine	thiazide	63	65	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	none	none	none
nifedipine	thiazide	63	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	none	none	none
nifedipine	thiazide	62	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	none	none	none
nifedipine	digoxin	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	none	none	none
nifedipine	digoxin	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	none	none	none
nifedipine	digoxin	63	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	none	none	none
nifedipine	digoxin	62	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	none	none	none
nifedipine	hydrochlorothiazide	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	5487	none	D006852
nifedipine	hydrochlorothiazide	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	5487	none	D006852
nifedipine	hydrochlorothiazide	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	5487	none	D006852
nifedipine	hydrochlorothiazide	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	5487	none	D006852
nifedipine	hydrochlorothiazide	65	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	5487	none	D006852
nifedipine	hydrochlorothiazide	65	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	5487	none	D006852
nifedipine	hydrochlorothiazide	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	5487	none	D006852
nifedipine	hydrochlorothiazide	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	5487	none	D006852
nifedipine	hydrochlorothiazide	63	65	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	5487	none	D006852
nifedipine	hydrochlorothiazide	63	65	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	5487	none	D006852
nifedipine	hydrochlorothiazide	63	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	5487	none	D006852
nifedipine	hydrochlorothiazide	63	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	5487	none	D006852
nifedipine	hydrochlorothiazide	62	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	5487	none	D006852
nifedipine	hydrochlorothiazide	62	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	5487	none	D006852
nifedipine	irbesartan	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	83818	none	83818
nifedipine	irbesartan	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	83818	none	83818
nifedipine	irbesartan	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	83818	none	83818
nifedipine	irbesartan	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	83818	none	83818
nifedipine	irbesartan	65	64	true	negative	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
nifedipine	irbesartan	65	64	true	negative	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
nifedipine	irbesartan	65	65	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
nifedipine	irbesartan	65	65	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
nifedipine	irbesartan	65	67	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	83818	none	83818
nifedipine	irbesartan	65	67	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	83818	none	83818
nifedipine	irbesartan	65	63	true	negative	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
nifedipine	irbesartan	65	63	true	negative	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
nifedipine	irbesartan	63	64	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	83818	none	83818
nifedipine	irbesartan	63	64	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	83818	none	83818
nifedipine	irbesartan	63	65	true	negative	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
nifedipine	irbesartan	63	65	true	negative	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
nifedipine	irbesartan	63	63	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	83818	none	83818
nifedipine	irbesartan	63	63	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	83818	none	83818
nifedipine	irbesartan	62	64	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	83818	none	83818
nifedipine	irbesartan	62	64	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	83818	none	83818
nifedipine	irbesartan	62	63	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	83818	none	83818
nifedipine	irbesartan	62	63	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	83818	none	83818
nifedipine	irbesartan	62	60	true	negative	Hepatic Insufficiency    The pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver.  No dosage adjustment is necessary in patients with hepatic insufficiency.  Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	83818	none	83818
nifedipine	irbesartan	62	60	true	negative	Hepatic Insufficiency    The pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver.  No dosage adjustment is necessary in patients with hepatic insufficiency.  Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	83818	none	83818
nifedipine	p450	68	66	false	none	Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	none	none	none
nifedipine	p450	65	66	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  		none	none	none	none
tolbutamide	Hydrochlorothiazide	63	65	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	5487	none	D006852
tolbutamide	Hydrochlorothiazide	63	65	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	5487	none	D006852
tolbutamide	Hydrochlorothiazide	63	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	5487	none	D006852
tolbutamide	Hydrochlorothiazide	63	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	5487	none	D006852
tolbutamide	Irbesartan	63	64	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	83818	none	83818
tolbutamide	Irbesartan	63	64	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	83818	none	83818
tolbutamide	Irbesartan	63	65	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
tolbutamide	Irbesartan	63	65	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
tolbutamide	Irbesartan	63	63	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	83818	none	83818
tolbutamide	Irbesartan	63	63	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	83818	none	83818
tolbutamide	warfarin	63	64	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	none	none	none
tolbutamide	warfarin	63	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	none	none	none
tolbutamide	thiazide	63	65	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	none	none	none
tolbutamide	thiazide	63	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	none	none	none
tolbutamide	digoxin	63	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	none	none	none
tolbutamide	hydrochlorothiazide	63	65	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	5487	none	D006852
tolbutamide	hydrochlorothiazide	63	65	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	5487	none	D006852
tolbutamide	hydrochlorothiazide	63	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	5487	none	D006852
tolbutamide	hydrochlorothiazide	63	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	5487	none	D006852
tolbutamide	irbesartan	63	64	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	83818	none	83818
tolbutamide	irbesartan	63	64	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	83818	none	83818
tolbutamide	irbesartan	63	65	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
tolbutamide	irbesartan	63	65	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
tolbutamide	irbesartan	63	63	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	83818	none	83818
tolbutamide	irbesartan	63	63	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	83818	none	83818
Hydrochlorothiazide	aldosterone	9	11	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		5487	1312358	D006852	1312358
Hydrochlorothiazide	aldosterone	9	11	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		5487	1312358	D006852	1312358
Hydrochlorothiazide	aldosterone	11	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		5487	1312358	D006852	1312358
Hydrochlorothiazide	aldosterone	11	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		5487	1312358	D006852	1312358
Hydrochlorothiazide	aldosterone	11	12	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  		5487	1312358	D006852	1312358
Hydrochlorothiazide	aldosterone	11	12	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  		5487	1312358	D006852	1312358
Hydrochlorothiazide	Irbesartan	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	49	47	false	none	Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	49	47	false	none	Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	49	51	true	positive	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  Gender    No gender-related differences in pharmacokinetics were observed in healthy elderly (age 65 to 80 years) or in healthy young (age 18 to 40 years) subjects.  In studies of hypertensive patients, there was no gender difference in half-life or accumulation, but somewhat higher plasma concentrations of irbesartan were observed in females (11% to 44%).  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	49	51	true	positive	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  Gender    No gender-related differences in pharmacokinetics were observed in healthy elderly (age 65 to 80 years) or in healthy young (age 18 to 40 years) subjects.  In studies of hypertensive patients, there was no gender difference in half-life or accumulation, but somewhat higher plasma concentrations of irbesartan were observed in females (11% to 44%).  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	49	49	false	none	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	49	49	false	none	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	48	46	false	none	Studies in animals indicate that radiolabeled irbesartan weakly crosses the blood-brain barrier and placenta.  Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	48	46	false	none	Studies in animals indicate that radiolabeled irbesartan weakly crosses the blood-brain barrier and placenta.  Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	48	47	false	none	Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	48	47	false	none	Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	48	49	false	none	Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	48	49	false	none	Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	21	23	false	none	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  12.3 Pharmacokinetics    Irbesartan    Irbesartan is an orally active agent that does not require biotransformation into an active form.  The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	21	23	false	none	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  12.3 Pharmacokinetics    Irbesartan    Irbesartan is an orally active agent that does not require biotransformation into an active form.  The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	21	22	true	positive	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  12.3 Pharmacokinetics    Irbesartan    Irbesartan is an orally active agent that does not require biotransformation into an active form.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	21	22	true	positive	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  12.3 Pharmacokinetics    Irbesartan    Irbesartan is an orally active agent that does not require biotransformation into an active form.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	65	64	true	negative	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	65	64	true	negative	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	65	65	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	65	65	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	65	67	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	65	67	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	65	63	true	negative	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	65	63	true	negative	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	67	65	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	67	65	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	9	7	false	none	Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis.  Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	9	7	false	none	Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis.  Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	9	8	false	none	Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	9	8	false	none	Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	40	38	true	negative	Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1).  There was no induction or inhibition of 3A4.  Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	40	38	true	negative	Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1).  There was no induction or inhibition of 3A4.  Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	40	42	false	none	Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  At least 61% of the oral dose is eliminated unchanged within 24 hours.  Distribution    Irbesartan    Irbesartan is 90% bound to serum proteins (primarily albumin and 1-acid glycoprotein) with negligible binding to cellular components of blood.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	40	42	false	none	Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  At least 61% of the oral dose is eliminated unchanged within 24 hours.  Distribution    Irbesartan    Irbesartan is 90% bound to serum proteins (primarily albumin and 1-acid glycoprotein) with negligible binding to cellular components of blood.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	62	64	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	62	64	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	62	63	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	62	63	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	62	60	true	negative	Hepatic Insufficiency    The pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver.  No dosage adjustment is necessary in patients with hepatic insufficiency.  Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	62	60	true	negative	Hepatic Insufficiency    The pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver.  No dosage adjustment is necessary in patients with hepatic insufficiency.  Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	30	29	true	positive	Limited accumulation of irbesartan (<20%) is observed in plasma upon repeated once-daily dosing.  Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	30	29	true	positive	Limited accumulation of irbesartan (<20%) is observed in plasma upon repeated once-daily dosing.  Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	30	31	false	none	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	30	31	false	none	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	30	32	true	positive	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  		5487	83818	D006852	83818
Hydrochlorothiazide	Irbesartan	30	32	true	positive	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  		5487	83818	D006852	83818
Hydrochlorothiazide	warfarin	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	none	D006852	none
Hydrochlorothiazide	warfarin	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	none	D006852	none
Hydrochlorothiazide	warfarin	65	64	false	none	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		5487	none	D006852	none
Hydrochlorothiazide	warfarin	65	64	false	none	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		5487	none	D006852	none
Hydrochlorothiazide	warfarin	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	none	D006852	none
Hydrochlorothiazide	warfarin	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	none	D006852	none
Hydrochlorothiazide	warfarin	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	none	D006852	none
Hydrochlorothiazide	warfarin	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	none	D006852	none
Hydrochlorothiazide	warfarin	62	64	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		5487	none	D006852	none
Hydrochlorothiazide	warfarin	62	64	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		5487	none	D006852	none
Hydrochlorothiazide	warfarin	62	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		5487	none	D006852	none
Hydrochlorothiazide	warfarin	62	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		5487	none	D006852	none
Hydrochlorothiazide	Aldosterone	9	11	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		5487	1312358	D006852	1312358
Hydrochlorothiazide	Aldosterone	9	11	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		5487	1312358	D006852	1312358
Hydrochlorothiazide	Aldosterone	11	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		5487	1312358	D006852	1312358
Hydrochlorothiazide	Aldosterone	11	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		5487	1312358	D006852	1312358
Hydrochlorothiazide	Aldosterone	11	12	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  		5487	1312358	D006852	1312358
Hydrochlorothiazide	Aldosterone	11	12	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  		5487	1312358	D006852	1312358
Hydrochlorothiazide	prothrombin	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	none	D006852	none
Hydrochlorothiazide	prothrombin	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	none	D006852	none
Hydrochlorothiazide	prothrombin	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	none	D006852	none
Hydrochlorothiazide	prothrombin	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	none	D006852	none
Hydrochlorothiazide	prothrombin	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	none	D006852	none
Hydrochlorothiazide	prothrombin	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	49	49	false	none	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	49	49	false	none	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	49	48	false	none	Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	49	48	false	none	Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	48	49	false	none	Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	48	49	false	none	Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	48	48	false	none	Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	48	48	false	none	Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	21	21	true	positive	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	21	21	true	positive	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	65	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	65	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	67	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	67	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	9	9	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	9	9	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	9	10	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	9	10	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	9	11	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	9	11	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	40	40	false	none	Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	40	40	false	none	Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	11	9	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	11	9	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	11	10	false	none	Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	11	10	false	none	Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	11	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	11	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	11	13	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  The mechanism of the antihypertensive effect of thiazides is not fully understood.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	11	13	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  The mechanism of the antihypertensive effect of thiazides is not fully understood.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	62	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	62	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	30	30	false	none	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  		5487	none	D006852	none
Hydrochlorothiazide	thiazide	30	30	false	none	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  		5487	none	D006852	none
Hydrochlorothiazide	digoxin	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	none	D006852	none
Hydrochlorothiazide	digoxin	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	none	D006852	none
Hydrochlorothiazide	digoxin	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	none	D006852	none
Hydrochlorothiazide	digoxin	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	none	D006852	none
Hydrochlorothiazide	digoxin	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	none	D006852	none
Hydrochlorothiazide	digoxin	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	none	D006852	none
Hydrochlorothiazide	digoxin	62	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		5487	none	D006852	none
Hydrochlorothiazide	digoxin	62	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		5487	none	D006852	none
Hydrochlorothiazide	irbesartan	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	49	47	false	none	Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	49	47	false	none	Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	49	51	true	positive	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  Gender    No gender-related differences in pharmacokinetics were observed in healthy elderly (age 65 to 80 years) or in healthy young (age 18 to 40 years) subjects.  In studies of hypertensive patients, there was no gender difference in half-life or accumulation, but somewhat higher plasma concentrations of irbesartan were observed in females (11% to 44%).  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	49	51	true	positive	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  Gender    No gender-related differences in pharmacokinetics were observed in healthy elderly (age 65 to 80 years) or in healthy young (age 18 to 40 years) subjects.  In studies of hypertensive patients, there was no gender difference in half-life or accumulation, but somewhat higher plasma concentrations of irbesartan were observed in females (11% to 44%).  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	49	49	false	none	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	49	49	false	none	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	48	46	false	none	Studies in animals indicate that radiolabeled irbesartan weakly crosses the blood-brain barrier and placenta.  Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	48	46	false	none	Studies in animals indicate that radiolabeled irbesartan weakly crosses the blood-brain barrier and placenta.  Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	48	47	false	none	Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	48	47	false	none	Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	48	49	false	none	Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	48	49	false	none	Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	21	23	false	none	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  12.3 Pharmacokinetics    Irbesartan    Irbesartan is an orally active agent that does not require biotransformation into an active form.  The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	21	23	false	none	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  12.3 Pharmacokinetics    Irbesartan    Irbesartan is an orally active agent that does not require biotransformation into an active form.  The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	21	22	true	positive	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  12.3 Pharmacokinetics    Irbesartan    Irbesartan is an orally active agent that does not require biotransformation into an active form.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	21	22	true	positive	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  12.3 Pharmacokinetics    Irbesartan    Irbesartan is an orally active agent that does not require biotransformation into an active form.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	65	64	true	negative	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	65	64	true	negative	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	65	65	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	65	65	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	65	67	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	65	67	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	65	63	true	negative	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	65	63	true	negative	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	67	65	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	67	65	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	9	7	false	none	Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis.  Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	9	7	false	none	Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis.  Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	9	8	false	none	Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	9	8	false	none	Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	40	38	true	negative	Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1).  There was no induction or inhibition of 3A4.  Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	40	38	true	negative	Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1).  There was no induction or inhibition of 3A4.  Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	40	42	false	none	Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  At least 61% of the oral dose is eliminated unchanged within 24 hours.  Distribution    Irbesartan    Irbesartan is 90% bound to serum proteins (primarily albumin and 1-acid glycoprotein) with negligible binding to cellular components of blood.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	40	42	false	none	Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  At least 61% of the oral dose is eliminated unchanged within 24 hours.  Distribution    Irbesartan    Irbesartan is 90% bound to serum proteins (primarily albumin and 1-acid glycoprotein) with negligible binding to cellular components of blood.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	62	64	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	62	64	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	62	63	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	62	63	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	62	60	true	negative	Hepatic Insufficiency    The pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver.  No dosage adjustment is necessary in patients with hepatic insufficiency.  Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	62	60	true	negative	Hepatic Insufficiency    The pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver.  No dosage adjustment is necessary in patients with hepatic insufficiency.  Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	30	29	true	positive	Limited accumulation of irbesartan (<20%) is observed in plasma upon repeated once-daily dosing.  Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	30	29	true	positive	Limited accumulation of irbesartan (<20%) is observed in plasma upon repeated once-daily dosing.  Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	30	31	false	none	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	30	31	false	none	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	30	32	true	positive	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  		5487	83818	D006852	83818
Hydrochlorothiazide	irbesartan	30	32	true	positive	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  		5487	83818	D006852	83818
Hydrochlorothiazide	glucuronide	30	31	false	none	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		5487	none	D006852	none
Hydrochlorothiazide	glucuronide	30	31	false	none	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		5487	none	D006852	none
Hydrochlorothiazide	cholesterol	21	19	true	negative	In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations.  There was no effect on serum uric acid during chronic oral administration and no uricosuric effect.  Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  		5487	2438	D006852	D002784
Hydrochlorothiazide	cholesterol	21	19	true	negative	In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations.  There was no effect on serum uric acid during chronic oral administration and no uricosuric effect.  Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  		5487	2438	D006852	D002784
Hydrochlorothiazide	p450	68	66	false	none	Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	none	D006852	none
Hydrochlorothiazide	p450	68	66	false	none	Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	none	D006852	none
Hydrochlorothiazide	p450	65	66	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  		5487	none	D006852	none
Hydrochlorothiazide	p450	65	66	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  		5487	none	D006852	none
Hydrochlorothiazide	p450	67	66	false	none	Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	none	D006852	none
Hydrochlorothiazide	p450	67	66	false	none	Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	none	D006852	none
aldosterone	Irbesartan	17	17	false	none	Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  		1312358	83818	1312358	83818
aldosterone	Irbesartan	17	17	false	none	Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  		1312358	83818	1312358	83818
aldosterone	Irbesartan	17	16	true	positive	In hypertensive patients, angiotensin II receptor inhibition following chronic administration of irbesartan causes a 1.5- to 2-fold rise in angiotensin II plasma concentration and a 2- to 3-fold increase in plasma renin levels.  Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  		1312358	83818	1312358	83818
aldosterone	Irbesartan	17	16	true	positive	In hypertensive patients, angiotensin II receptor inhibition following chronic administration of irbesartan causes a 1.5- to 2-fold rise in angiotensin II plasma concentration and a 2- to 3-fold increase in plasma renin levels.  Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  		1312358	83818	1312358	83818
aldosterone	Irbesartan	17	18	false	none	Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction.  		1312358	83818	1312358	83818
aldosterone	Irbesartan	17	18	false	none	Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction.  		1312358	83818	1312358	83818
aldosterone	Irbesartan	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Irbesartan    Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).  Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.  		1312358	83818	1312358	83818
aldosterone	Irbesartan	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Irbesartan    Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).  Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.  		1312358	83818	1312358	83818
aldosterone	Irbesartan	2	3	false	none	Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.  Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  		1312358	83818	1312358	83818
aldosterone	Irbesartan	2	3	false	none	Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.  Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  		1312358	83818	1312358	83818
aldosterone	Irbesartan	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Irbesartan    Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).  Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.  Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  		1312358	83818	1312358	83818
aldosterone	Irbesartan	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Irbesartan    Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).  Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.  Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  		1312358	83818	1312358	83818
aldosterone	Irbesartan	3	3	false	none	Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  		1312358	83818	1312358	83818
aldosterone	Irbesartan	3	3	false	none	Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  		1312358	83818	1312358	83818
aldosterone	Irbesartan	3	5	false	none	Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  There is also an AT2 receptor in many tissues, but it is not involved in cardiovascular homeostasis.  Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor, and no agonist activity.  		1312358	83818	1312358	83818
aldosterone	Irbesartan	3	5	false	none	Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  There is also an AT2 receptor in many tissues, but it is not involved in cardiovascular homeostasis.  Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor, and no agonist activity.  		1312358	83818	1312358	83818
aldosterone	Irbesartan	12	14	false	none	The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  The mechanism of the antihypertensive effect of thiazides is not fully understood.  12.2 Pharmacodynamics    Irbesartan    In healthy subjects, single oral irbesartan doses of up to 300 mg produced dose-dependent inhibition of the pressor effect of angiotensin II infusions.  		1312358	83818	1312358	83818
aldosterone	Irbesartan	12	14	false	none	The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  The mechanism of the antihypertensive effect of thiazides is not fully understood.  12.2 Pharmacodynamics    Irbesartan    In healthy subjects, single oral irbesartan doses of up to 300 mg produced dose-dependent inhibition of the pressor effect of angiotensin II infusions.  		1312358	83818	1312358	83818
aldosterone	thiazide	11	9	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		1312358	none	1312358	none
aldosterone	thiazide	11	9	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		1312358	none	1312358	none
aldosterone	thiazide	11	10	false	none	Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		1312358	none	1312358	none
aldosterone	thiazide	11	10	false	none	Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		1312358	none	1312358	none
aldosterone	thiazide	11	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		1312358	none	1312358	none
aldosterone	thiazide	11	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		1312358	none	1312358	none
aldosterone	thiazide	11	13	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  The mechanism of the antihypertensive effect of thiazides is not fully understood.  		1312358	none	1312358	none
aldosterone	thiazide	11	13	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  The mechanism of the antihypertensive effect of thiazides is not fully understood.  		1312358	none	1312358	none
aldosterone	thiazide	12	10	false	none	Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  		1312358	none	1312358	none
aldosterone	thiazide	12	10	false	none	Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  		1312358	none	1312358	none
aldosterone	thiazide	12	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  		1312358	none	1312358	none
aldosterone	thiazide	12	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  		1312358	none	1312358	none
aldosterone	thiazide	12	13	false	none	The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  The mechanism of the antihypertensive effect of thiazides is not fully understood.  		1312358	none	1312358	none
aldosterone	thiazide	12	13	false	none	The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  The mechanism of the antihypertensive effect of thiazides is not fully understood.  		1312358	none	1312358	none
aldosterone	hydrochlorothiazide	11	9	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		1312358	5487	1312358	D006852
aldosterone	hydrochlorothiazide	11	9	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		1312358	5487	1312358	D006852
aldosterone	hydrochlorothiazide	11	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		1312358	5487	1312358	D006852
aldosterone	hydrochlorothiazide	11	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		1312358	5487	1312358	D006852
aldosterone	hydrochlorothiazide	12	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  		1312358	5487	1312358	D006852
aldosterone	hydrochlorothiazide	12	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  		1312358	5487	1312358	D006852
aldosterone	irbesartan	17	17	false	none	Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  		1312358	83818	1312358	83818
aldosterone	irbesartan	17	17	false	none	Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  		1312358	83818	1312358	83818
aldosterone	irbesartan	17	16	true	positive	In hypertensive patients, angiotensin II receptor inhibition following chronic administration of irbesartan causes a 1.5- to 2-fold rise in angiotensin II plasma concentration and a 2- to 3-fold increase in plasma renin levels.  Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  		1312358	83818	1312358	83818
aldosterone	irbesartan	17	16	true	positive	In hypertensive patients, angiotensin II receptor inhibition following chronic administration of irbesartan causes a 1.5- to 2-fold rise in angiotensin II plasma concentration and a 2- to 3-fold increase in plasma renin levels.  Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  		1312358	83818	1312358	83818
aldosterone	irbesartan	17	18	false	none	Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction.  		1312358	83818	1312358	83818
aldosterone	irbesartan	17	18	false	none	Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction.  		1312358	83818	1312358	83818
aldosterone	irbesartan	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Irbesartan    Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).  Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.  		1312358	83818	1312358	83818
aldosterone	irbesartan	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Irbesartan    Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).  Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.  		1312358	83818	1312358	83818
aldosterone	irbesartan	2	3	false	none	Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.  Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  		1312358	83818	1312358	83818
aldosterone	irbesartan	2	3	false	none	Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.  Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  		1312358	83818	1312358	83818
aldosterone	irbesartan	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Irbesartan    Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).  Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.  Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  		1312358	83818	1312358	83818
aldosterone	irbesartan	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Irbesartan    Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).  Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.  Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  		1312358	83818	1312358	83818
aldosterone	irbesartan	3	3	false	none	Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  		1312358	83818	1312358	83818
aldosterone	irbesartan	3	3	false	none	Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  		1312358	83818	1312358	83818
aldosterone	irbesartan	3	5	false	none	Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  There is also an AT2 receptor in many tissues, but it is not involved in cardiovascular homeostasis.  Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor, and no agonist activity.  		1312358	83818	1312358	83818
aldosterone	irbesartan	3	5	false	none	Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  There is also an AT2 receptor in many tissues, but it is not involved in cardiovascular homeostasis.  Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor, and no agonist activity.  		1312358	83818	1312358	83818
aldosterone	irbesartan	12	14	false	none	The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  The mechanism of the antihypertensive effect of thiazides is not fully understood.  12.2 Pharmacodynamics    Irbesartan    In healthy subjects, single oral irbesartan doses of up to 300 mg produced dose-dependent inhibition of the pressor effect of angiotensin II infusions.  		1312358	83818	1312358	83818
aldosterone	irbesartan	12	14	false	none	The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  The mechanism of the antihypertensive effect of thiazides is not fully understood.  12.2 Pharmacodynamics    Irbesartan    In healthy subjects, single oral irbesartan doses of up to 300 mg produced dose-dependent inhibition of the pressor effect of angiotensin II infusions.  		1312358	83818	1312358	83818
aldosterone	cholesterol	17	19	false	none	Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction.  In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations.  		1312358	2438	1312358	D002784
aldosterone	cholesterol	17	19	false	none	Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction.  In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations.  		1312358	2438	1312358	D002784
Irbesartan	warfarin	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		83818	none	83818	none
Irbesartan	warfarin	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		83818	none	83818	none
Irbesartan	warfarin	64	64	false	none	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		83818	none	83818	none
Irbesartan	warfarin	64	64	false	none	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		83818	none	83818	none
Irbesartan	warfarin	64	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		83818	none	83818	none
Irbesartan	warfarin	64	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		83818	none	83818	none
Irbesartan	warfarin	65	64	false	none	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		83818	none	83818	none
Irbesartan	warfarin	65	64	false	none	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		83818	none	83818	none
Irbesartan	warfarin	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	none	83818	none
Irbesartan	warfarin	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	none	83818	none
Irbesartan	warfarin	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	none	83818	none
Irbesartan	warfarin	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	none	83818	none
Irbesartan	warfarin	63	64	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		83818	none	83818	none
Irbesartan	warfarin	63	64	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		83818	none	83818	none
Irbesartan	warfarin	63	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		83818	none	83818	none
Irbesartan	warfarin	63	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		83818	none	83818	none
Irbesartan	warfarin	60	62	true	negative	Hepatic Insufficiency    The pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver.  No dosage adjustment is necessary in patients with hepatic insufficiency.  Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		83818	none	83818	none
Irbesartan	warfarin	60	62	true	negative	Hepatic Insufficiency    The pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver.  No dosage adjustment is necessary in patients with hepatic insufficiency.  Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		83818	none	83818	none
Irbesartan	Aldosterone	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Irbesartan    Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).  Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.  		83818	1312358	83818	1312358
Irbesartan	Aldosterone	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Irbesartan    Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).  Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.  		83818	1312358	83818	1312358
Irbesartan	Aldosterone	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Irbesartan    Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).  Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.  Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  		83818	1312358	83818	1312358
Irbesartan	Aldosterone	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Irbesartan    Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).  Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.  Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  		83818	1312358	83818	1312358
Irbesartan	Aldosterone	3	2	false	none	Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.  Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  		83818	1312358	83818	1312358
Irbesartan	Aldosterone	3	2	false	none	Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.  Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  		83818	1312358	83818	1312358
Irbesartan	Aldosterone	3	3	false	none	Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  		83818	1312358	83818	1312358
Irbesartan	Aldosterone	3	3	false	none	Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  		83818	1312358	83818	1312358
Irbesartan	Aldosterone	5	3	false	none	Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  There is also an AT2 receptor in many tissues, but it is not involved in cardiovascular homeostasis.  Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor, and no agonist activity.  		83818	1312358	83818	1312358
Irbesartan	Aldosterone	5	3	false	none	Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  There is also an AT2 receptor in many tissues, but it is not involved in cardiovascular homeostasis.  Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor, and no agonist activity.  		83818	1312358	83818	1312358
Irbesartan	Aldosterone	14	12	false	none	The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  The mechanism of the antihypertensive effect of thiazides is not fully understood.  12.2 Pharmacodynamics    Irbesartan    In healthy subjects, single oral irbesartan doses of up to 300 mg produced dose-dependent inhibition of the pressor effect of angiotensin II infusions.  		83818	1312358	83818	1312358
Irbesartan	Aldosterone	14	12	false	none	The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  The mechanism of the antihypertensive effect of thiazides is not fully understood.  12.2 Pharmacodynamics    Irbesartan    In healthy subjects, single oral irbesartan doses of up to 300 mg produced dose-dependent inhibition of the pressor effect of angiotensin II infusions.  		83818	1312358	83818	1312358
Irbesartan	Aldosterone	17	17	false	none	Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  		83818	1312358	83818	1312358
Irbesartan	Aldosterone	17	17	false	none	Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  		83818	1312358	83818	1312358
Irbesartan	Aldosterone	16	17	true	positive	In hypertensive patients, angiotensin II receptor inhibition following chronic administration of irbesartan causes a 1.5- to 2-fold rise in angiotensin II plasma concentration and a 2- to 3-fold increase in plasma renin levels.  Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  		83818	1312358	83818	1312358
Irbesartan	Aldosterone	16	17	true	positive	In hypertensive patients, angiotensin II receptor inhibition following chronic administration of irbesartan causes a 1.5- to 2-fold rise in angiotensin II plasma concentration and a 2- to 3-fold increase in plasma renin levels.  Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  		83818	1312358	83818	1312358
Irbesartan	Aldosterone	18	17	false	none	Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction.  		83818	1312358	83818	1312358
Irbesartan	Aldosterone	18	17	false	none	Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction.  		83818	1312358	83818	1312358
Irbesartan	prothrombin	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		83818	none	83818	none
Irbesartan	prothrombin	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		83818	none	83818	none
Irbesartan	prothrombin	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	none	83818	none
Irbesartan	prothrombin	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	none	83818	none
Irbesartan	prothrombin	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	none	83818	none
Irbesartan	prothrombin	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	none	83818	none
Irbesartan	thiazide	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		83818	none	83818	none
Irbesartan	thiazide	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		83818	none	83818	none
Irbesartan	thiazide	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		83818	none	83818	none
Irbesartan	thiazide	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		83818	none	83818	none
Irbesartan	thiazide	64	65	false	none	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		83818	none	83818	none
Irbesartan	thiazide	64	65	false	none	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		83818	none	83818	none
Irbesartan	thiazide	64	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		83818	none	83818	none
Irbesartan	thiazide	64	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		83818	none	83818	none
Irbesartan	thiazide	65	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		83818	none	83818	none
Irbesartan	thiazide	65	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		83818	none	83818	none
Irbesartan	thiazide	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	none	83818	none
Irbesartan	thiazide	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	none	83818	none
Irbesartan	thiazide	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		83818	none	83818	none
Irbesartan	thiazide	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		83818	none	83818	none
Irbesartan	thiazide	67	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	none	83818	none
Irbesartan	thiazide	67	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	none	83818	none
Irbesartan	thiazide	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	none	83818	none
Irbesartan	thiazide	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	none	83818	none
Irbesartan	thiazide	7	9	false	none	Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis.  Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		83818	none	83818	none
Irbesartan	thiazide	7	9	false	none	Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis.  Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		83818	none	83818	none
Irbesartan	thiazide	8	9	false	none	Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		83818	none	83818	none
Irbesartan	thiazide	8	9	false	none	Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		83818	none	83818	none
Irbesartan	thiazide	8	10	false	none	Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  		83818	none	83818	none
Irbesartan	thiazide	8	10	false	none	Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  		83818	none	83818	none
Irbesartan	thiazide	14	13	false	none	The mechanism of the antihypertensive effect of thiazides is not fully understood.  12.2 Pharmacodynamics    Irbesartan    In healthy subjects, single oral irbesartan doses of up to 300 mg produced dose-dependent inhibition of the pressor effect of angiotensin II infusions.  		83818	none	83818	none
Irbesartan	thiazide	14	13	false	none	The mechanism of the antihypertensive effect of thiazides is not fully understood.  12.2 Pharmacodynamics    Irbesartan    In healthy subjects, single oral irbesartan doses of up to 300 mg produced dose-dependent inhibition of the pressor effect of angiotensin II infusions.  		83818	none	83818	none
Irbesartan	thiazide	23	21	false	none	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  12.3 Pharmacokinetics    Irbesartan    Irbesartan is an orally active agent that does not require biotransformation into an active form.  The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.  		83818	none	83818	none
Irbesartan	thiazide	23	21	false	none	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  12.3 Pharmacokinetics    Irbesartan    Irbesartan is an orally active agent that does not require biotransformation into an active form.  The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.  		83818	none	83818	none
Irbesartan	thiazide	22	21	true	positive	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  12.3 Pharmacokinetics    Irbesartan    Irbesartan is an orally active agent that does not require biotransformation into an active form.  		83818	none	83818	none
Irbesartan	thiazide	22	21	true	positive	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  12.3 Pharmacokinetics    Irbesartan    Irbesartan is an orally active agent that does not require biotransformation into an active form.  		83818	none	83818	none
Irbesartan	thiazide	29	30	true	positive	Limited accumulation of irbesartan (<20%) is observed in plasma upon repeated once-daily dosing.  Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  		83818	none	83818	none
Irbesartan	thiazide	29	30	true	positive	Limited accumulation of irbesartan (<20%) is observed in plasma upon repeated once-daily dosing.  Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  		83818	none	83818	none
Irbesartan	thiazide	31	30	false	none	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		83818	none	83818	none
Irbesartan	thiazide	31	30	false	none	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		83818	none	83818	none
Irbesartan	thiazide	32	30	true	positive	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  		83818	none	83818	none
Irbesartan	thiazide	32	30	true	positive	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  		83818	none	83818	none
Irbesartan	thiazide	38	40	true	negative	Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1).  There was no induction or inhibition of 3A4.  Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  		83818	none	83818	none
Irbesartan	thiazide	38	40	true	negative	Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1).  There was no induction or inhibition of 3A4.  Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  		83818	none	83818	none
Irbesartan	thiazide	42	40	false	none	Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  At least 61% of the oral dose is eliminated unchanged within 24 hours.  Distribution    Irbesartan    Irbesartan is 90% bound to serum proteins (primarily albumin and 1-acid glycoprotein) with negligible binding to cellular components of blood.  		83818	none	83818	none
Irbesartan	thiazide	42	40	false	none	Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  At least 61% of the oral dose is eliminated unchanged within 24 hours.  Distribution    Irbesartan    Irbesartan is 90% bound to serum proteins (primarily albumin and 1-acid glycoprotein) with negligible binding to cellular components of blood.  		83818	none	83818	none
Irbesartan	thiazide	46	48	false	none	Studies in animals indicate that radiolabeled irbesartan weakly crosses the blood-brain barrier and placenta.  Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		83818	none	83818	none
Irbesartan	thiazide	46	48	false	none	Studies in animals indicate that radiolabeled irbesartan weakly crosses the blood-brain barrier and placenta.  Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		83818	none	83818	none
Irbesartan	thiazide	47	49	false	none	Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		83818	none	83818	none
Irbesartan	thiazide	47	49	false	none	Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		83818	none	83818	none
Irbesartan	thiazide	47	48	false	none	Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		83818	none	83818	none
Irbesartan	thiazide	47	48	false	none	Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		83818	none	83818	none
Irbesartan	thiazide	51	49	true	positive	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  Gender    No gender-related differences in pharmacokinetics were observed in healthy elderly (age 65 to 80 years) or in healthy young (age 18 to 40 years) subjects.  In studies of hypertensive patients, there was no gender difference in half-life or accumulation, but somewhat higher plasma concentrations of irbesartan were observed in females (11% to 44%).  		83818	none	83818	none
Irbesartan	thiazide	51	49	true	positive	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  Gender    No gender-related differences in pharmacokinetics were observed in healthy elderly (age 65 to 80 years) or in healthy young (age 18 to 40 years) subjects.  In studies of hypertensive patients, there was no gender difference in half-life or accumulation, but somewhat higher plasma concentrations of irbesartan were observed in females (11% to 44%).  		83818	none	83818	none
Irbesartan	thiazide	49	49	false	none	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		83818	none	83818	none
Irbesartan	thiazide	49	49	false	none	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		83818	none	83818	none
Irbesartan	thiazide	49	48	false	none	Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		83818	none	83818	none
Irbesartan	thiazide	49	48	false	none	Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		83818	none	83818	none
Irbesartan	thiazide	63	65	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		83818	none	83818	none
Irbesartan	thiazide	63	65	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		83818	none	83818	none
Irbesartan	thiazide	63	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		83818	none	83818	none
Irbesartan	thiazide	63	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		83818	none	83818	none
Irbesartan	thiazide	60	62	false	none	Hepatic Insufficiency    The pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver.  No dosage adjustment is necessary in patients with hepatic insufficiency.  Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		83818	none	83818	none
Irbesartan	thiazide	60	62	false	none	Hepatic Insufficiency    The pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver.  No dosage adjustment is necessary in patients with hepatic insufficiency.  Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		83818	none	83818	none
Irbesartan	digoxin	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		83818	none	83818	none
Irbesartan	digoxin	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		83818	none	83818	none
Irbesartan	digoxin	64	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		83818	none	83818	none
Irbesartan	digoxin	64	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		83818	none	83818	none
Irbesartan	digoxin	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	none	83818	none
Irbesartan	digoxin	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	none	83818	none
Irbesartan	digoxin	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	none	83818	none
Irbesartan	digoxin	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	none	83818	none
Irbesartan	digoxin	63	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		83818	none	83818	none
Irbesartan	digoxin	63	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		83818	none	83818	none
Irbesartan	digoxin	60	62	true	negative	Hepatic Insufficiency    The pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver.  No dosage adjustment is necessary in patients with hepatic insufficiency.  Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		83818	none	83818	none
Irbesartan	digoxin	60	62	true	negative	Hepatic Insufficiency    The pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver.  No dosage adjustment is necessary in patients with hepatic insufficiency.  Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		83818	none	83818	none
Irbesartan	hydrochlorothiazide	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	64	65	true	negative	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	64	65	true	negative	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	64	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	64	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	65	65	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	65	65	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	65	67	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	65	67	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	67	65	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	67	65	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	7	9	false	none	Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis.  Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	7	9	false	none	Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis.  Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	8	9	false	none	Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	8	9	false	none	Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	23	21	false	none	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  12.3 Pharmacokinetics    Irbesartan    Irbesartan is an orally active agent that does not require biotransformation into an active form.  The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	23	21	false	none	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  12.3 Pharmacokinetics    Irbesartan    Irbesartan is an orally active agent that does not require biotransformation into an active form.  The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	22	21	true	positive	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  12.3 Pharmacokinetics    Irbesartan    Irbesartan is an orally active agent that does not require biotransformation into an active form.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	22	21	true	positive	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  12.3 Pharmacokinetics    Irbesartan    Irbesartan is an orally active agent that does not require biotransformation into an active form.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	29	30	true	positive	Limited accumulation of irbesartan (<20%) is observed in plasma upon repeated once-daily dosing.  Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	29	30	true	positive	Limited accumulation of irbesartan (<20%) is observed in plasma upon repeated once-daily dosing.  Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	31	30	false	none	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	31	30	false	none	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	32	30	true	positive	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	32	30	true	positive	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	38	40	true	negative	Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1).  There was no induction or inhibition of 3A4.  Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	38	40	true	negative	Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1).  There was no induction or inhibition of 3A4.  Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	42	40	false	none	Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  At least 61% of the oral dose is eliminated unchanged within 24 hours.  Distribution    Irbesartan    Irbesartan is 90% bound to serum proteins (primarily albumin and 1-acid glycoprotein) with negligible binding to cellular components of blood.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	42	40	false	none	Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  At least 61% of the oral dose is eliminated unchanged within 24 hours.  Distribution    Irbesartan    Irbesartan is 90% bound to serum proteins (primarily albumin and 1-acid glycoprotein) with negligible binding to cellular components of blood.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	46	48	false	none	Studies in animals indicate that radiolabeled irbesartan weakly crosses the blood-brain barrier and placenta.  Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	46	48	false	none	Studies in animals indicate that radiolabeled irbesartan weakly crosses the blood-brain barrier and placenta.  Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	47	49	false	none	Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	47	49	false	none	Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	47	48	false	none	Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	47	48	false	none	Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	51	49	true	positive	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  Gender    No gender-related differences in pharmacokinetics were observed in healthy elderly (age 65 to 80 years) or in healthy young (age 18 to 40 years) subjects.  In studies of hypertensive patients, there was no gender difference in half-life or accumulation, but somewhat higher plasma concentrations of irbesartan were observed in females (11% to 44%).  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	51	49	true	positive	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  Gender    No gender-related differences in pharmacokinetics were observed in healthy elderly (age 65 to 80 years) or in healthy young (age 18 to 40 years) subjects.  In studies of hypertensive patients, there was no gender difference in half-life or accumulation, but somewhat higher plasma concentrations of irbesartan were observed in females (11% to 44%).  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	49	49	false	none	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	49	49	false	none	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	49	48	false	none	Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	49	48	false	none	Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	63	65	true	negative	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	63	65	true	negative	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	63	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	63	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	60	62	true	negative	Hepatic Insufficiency    The pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver.  No dosage adjustment is necessary in patients with hepatic insufficiency.  Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		83818	5487	83818	D006852
Irbesartan	hydrochlorothiazide	60	62	true	negative	Hepatic Insufficiency    The pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver.  No dosage adjustment is necessary in patients with hepatic insufficiency.  Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		83818	5487	83818	D006852
Irbesartan	glucuronide	29	31	false	none	Limited accumulation of irbesartan (<20%) is observed in plasma upon repeated once-daily dosing.  Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		83818	none	83818	none
Irbesartan	glucuronide	29	31	false	none	Limited accumulation of irbesartan (<20%) is observed in plasma upon repeated once-daily dosing.  Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		83818	none	83818	none
Irbesartan	glucuronide	31	33	false	none	Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%).  		83818	none	83818	none
Irbesartan	glucuronide	31	33	false	none	Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%).  		83818	none	83818	none
Irbesartan	glucuronide	31	31	false	none	Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		83818	none	83818	none
Irbesartan	glucuronide	31	31	false	none	Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		83818	none	83818	none
Irbesartan	glucuronide	34	33	false	none	The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%).  The remaining oxidative metabolites do not add appreciably to irbesartans pharmacologic activity.  		83818	none	83818	none
Irbesartan	glucuronide	34	33	false	none	The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%).  The remaining oxidative metabolites do not add appreciably to irbesartans pharmacologic activity.  		83818	none	83818	none
Irbesartan	glucuronide	34	36	false	none	The remaining oxidative metabolites do not add appreciably to irbesartans pharmacologic activity.  Irbesartan and its metabolites are excreted by both biliary and renal routes.  Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  		83818	none	83818	none
Irbesartan	glucuronide	34	36	false	none	The remaining oxidative metabolites do not add appreciably to irbesartans pharmacologic activity.  Irbesartan and its metabolites are excreted by both biliary and renal routes.  Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  		83818	none	83818	none
Irbesartan	glucuronide	35	33	false	none	The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%).  The remaining oxidative metabolites do not add appreciably to irbesartans pharmacologic activity.  Irbesartan and its metabolites are excreted by both biliary and renal routes.  		83818	none	83818	none
Irbesartan	glucuronide	35	33	false	none	The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%).  The remaining oxidative metabolites do not add appreciably to irbesartans pharmacologic activity.  Irbesartan and its metabolites are excreted by both biliary and renal routes.  		83818	none	83818	none
Irbesartan	glucuronide	35	36	true	positive	Irbesartan and its metabolites are excreted by both biliary and renal routes.  Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  		83818	none	83818	none
Irbesartan	glucuronide	35	36	true	positive	Irbesartan and its metabolites are excreted by both biliary and renal routes.  Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  		83818	none	83818	none
Irbesartan	glucuronide	32	33	true	positive	Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%).  		83818	none	83818	none
Irbesartan	glucuronide	32	33	true	positive	Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%).  		83818	none	83818	none
Irbesartan	glucuronide	32	31	true	positive	Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  		83818	none	83818	none
Irbesartan	glucuronide	32	31	true	positive	Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  		83818	none	83818	none
Irbesartan	glucuronide	33	33	false	none	The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%).  		83818	none	83818	none
Irbesartan	glucuronide	33	33	false	none	The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%).  		83818	none	83818	none
Irbesartan	glucuronide	33	31	false	none	Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%).  		83818	none	83818	none
Irbesartan	glucuronide	33	31	false	none	Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%).  		83818	none	83818	none
Irbesartan	glucuronide	38	36	true	positive	Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1).  		83818	none	83818	none
Irbesartan	glucuronide	38	36	true	positive	Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1).  		83818	none	83818	none
Irbesartan	glucuronide	36	36	true	positive	Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  		83818	none	83818	none
Irbesartan	glucuronide	36	36	true	positive	Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  		83818	none	83818	none
Irbesartan	glucuronide	37	36	true	positive	Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  		83818	none	83818	none
Irbesartan	glucuronide	37	36	true	positive	Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  		83818	none	83818	none
Irbesartan	cholesterol	17	19	false	none	Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction.  In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations.  		83818	2438	83818	D002784
Irbesartan	cholesterol	17	19	false	none	Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction.  In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations.  		83818	2438	83818	D002784
Irbesartan	cholesterol	18	19	false	none	In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction.  In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations.  		83818	2438	83818	D002784
Irbesartan	cholesterol	18	19	false	none	In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction.  In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations.  		83818	2438	83818	D002784
Irbesartan	p450	68	66	false	none	Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		83818	none	83818	none
Irbesartan	p450	68	66	false	none	Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		83818	none	83818	none
Irbesartan	p450	64	66	false	none	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  		83818	none	83818	none
Irbesartan	p450	64	66	false	none	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  		83818	none	83818	none
Irbesartan	p450	65	66	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  		83818	none	83818	none
Irbesartan	p450	65	66	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  		83818	none	83818	none
Irbesartan	p450	67	66	false	none	Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	none	83818	none
Irbesartan	p450	67	66	false	none	Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	none	83818	none
Irbesartan	p450	35	37	true	positive	Irbesartan and its metabolites are excreted by both biliary and renal routes.  Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  		83818	none	83818	none
Irbesartan	p450	35	37	true	positive	Irbesartan and its metabolites are excreted by both biliary and renal routes.  Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  		83818	none	83818	none
Irbesartan	p450	38	37	true	positive	In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1).  		83818	none	83818	none
Irbesartan	p450	38	37	true	positive	In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1).  		83818	none	83818	none
Irbesartan	p450	36	37	true	positive	Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  		83818	none	83818	none
Irbesartan	p450	36	37	true	positive	Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  		83818	none	83818	none
Irbesartan	p450	37	37	false	none	In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  		83818	none	83818	none
Irbesartan	p450	37	37	false	none	In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  		83818	none	83818	none
warfarin	prothrombin	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	none	none	none
warfarin	thiazide	64	65	false	none	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	none	none	none
warfarin	thiazide	64	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	none	none	none
warfarin	thiazide	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	none	none	none
warfarin	thiazide	67	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	none	none	none
warfarin	thiazide	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	none	none	none
warfarin	thiazide	62	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	none	none	none
warfarin	digoxin	64	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	none	none	none
warfarin	digoxin	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	none	none	none
warfarin	digoxin	62	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	none	none	none
warfarin	hydrochlorothiazide	64	65	false	none	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	5487	none	D006852
warfarin	hydrochlorothiazide	64	65	false	none	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	5487	none	D006852
warfarin	hydrochlorothiazide	64	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	5487	none	D006852
warfarin	hydrochlorothiazide	64	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	5487	none	D006852
warfarin	hydrochlorothiazide	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	5487	none	D006852
warfarin	hydrochlorothiazide	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	5487	none	D006852
warfarin	hydrochlorothiazide	67	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	5487	none	D006852
warfarin	hydrochlorothiazide	67	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	5487	none	D006852
warfarin	hydrochlorothiazide	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	5487	none	D006852
warfarin	hydrochlorothiazide	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	5487	none	D006852
warfarin	hydrochlorothiazide	62	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	5487	none	D006852
warfarin	hydrochlorothiazide	62	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	5487	none	D006852
warfarin	irbesartan	64	64	false	none	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	83818	none	83818
warfarin	irbesartan	64	64	false	none	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	83818	none	83818
warfarin	irbesartan	64	65	false	none	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
warfarin	irbesartan	64	65	false	none	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
warfarin	irbesartan	64	63	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	83818	none	83818
warfarin	irbesartan	64	63	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	83818	none	83818
warfarin	irbesartan	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	83818	none	83818
warfarin	irbesartan	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	83818	none	83818
warfarin	irbesartan	67	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	83818	none	83818
warfarin	irbesartan	67	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	83818	none	83818
warfarin	irbesartan	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	83818	none	83818
warfarin	irbesartan	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	83818	none	83818
warfarin	irbesartan	62	64	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	83818	none	83818
warfarin	irbesartan	62	64	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	83818	none	83818
warfarin	irbesartan	62	63	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	83818	none	83818
warfarin	irbesartan	62	63	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	83818	none	83818
warfarin	irbesartan	62	60	true	negative	Hepatic Insufficiency    The pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver.  No dosage adjustment is necessary in patients with hepatic insufficiency.  Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	83818	none	83818
warfarin	irbesartan	62	60	true	negative	Hepatic Insufficiency    The pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver.  No dosage adjustment is necessary in patients with hepatic insufficiency.  Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	83818	none	83818
warfarin	p450	64	66	false	none	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  		none	none	none	none
warfarin	p450	67	66	false	none	Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	none	none	none
Aldosterone	thiazide	11	9	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		1312358	none	1312358	none
Aldosterone	thiazide	11	9	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		1312358	none	1312358	none
Aldosterone	thiazide	11	10	false	none	Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		1312358	none	1312358	none
Aldosterone	thiazide	11	10	false	none	Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		1312358	none	1312358	none
Aldosterone	thiazide	11	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		1312358	none	1312358	none
Aldosterone	thiazide	11	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		1312358	none	1312358	none
Aldosterone	thiazide	11	13	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  The mechanism of the antihypertensive effect of thiazides is not fully understood.  		1312358	none	1312358	none
Aldosterone	thiazide	11	13	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  The mechanism of the antihypertensive effect of thiazides is not fully understood.  		1312358	none	1312358	none
Aldosterone	thiazide	12	10	false	none	Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  		1312358	none	1312358	none
Aldosterone	thiazide	12	10	false	none	Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  		1312358	none	1312358	none
Aldosterone	thiazide	12	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  		1312358	none	1312358	none
Aldosterone	thiazide	12	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  		1312358	none	1312358	none
Aldosterone	thiazide	12	13	false	none	The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  The mechanism of the antihypertensive effect of thiazides is not fully understood.  		1312358	none	1312358	none
Aldosterone	thiazide	12	13	false	none	The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  The mechanism of the antihypertensive effect of thiazides is not fully understood.  		1312358	none	1312358	none
Aldosterone	hydrochlorothiazide	11	9	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		1312358	5487	1312358	D006852
Aldosterone	hydrochlorothiazide	11	9	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		1312358	5487	1312358	D006852
Aldosterone	hydrochlorothiazide	11	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		1312358	5487	1312358	D006852
Aldosterone	hydrochlorothiazide	11	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		1312358	5487	1312358	D006852
Aldosterone	hydrochlorothiazide	12	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  		1312358	5487	1312358	D006852
Aldosterone	hydrochlorothiazide	12	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  		1312358	5487	1312358	D006852
Aldosterone	irbesartan	17	17	false	none	Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  		1312358	83818	1312358	83818
Aldosterone	irbesartan	17	17	false	none	Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  		1312358	83818	1312358	83818
Aldosterone	irbesartan	17	16	true	positive	In hypertensive patients, angiotensin II receptor inhibition following chronic administration of irbesartan causes a 1.5- to 2-fold rise in angiotensin II plasma concentration and a 2- to 3-fold increase in plasma renin levels.  Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  		1312358	83818	1312358	83818
Aldosterone	irbesartan	17	16	true	positive	In hypertensive patients, angiotensin II receptor inhibition following chronic administration of irbesartan causes a 1.5- to 2-fold rise in angiotensin II plasma concentration and a 2- to 3-fold increase in plasma renin levels.  Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  		1312358	83818	1312358	83818
Aldosterone	irbesartan	17	18	false	none	Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction.  		1312358	83818	1312358	83818
Aldosterone	irbesartan	17	18	false	none	Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction.  		1312358	83818	1312358	83818
Aldosterone	irbesartan	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Irbesartan    Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).  Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.  		1312358	83818	1312358	83818
Aldosterone	irbesartan	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Irbesartan    Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).  Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.  		1312358	83818	1312358	83818
Aldosterone	irbesartan	2	3	false	none	Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.  Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  		1312358	83818	1312358	83818
Aldosterone	irbesartan	2	3	false	none	Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.  Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  		1312358	83818	1312358	83818
Aldosterone	irbesartan	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Irbesartan    Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).  Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.  Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  		1312358	83818	1312358	83818
Aldosterone	irbesartan	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Irbesartan    Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).  Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.  Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  		1312358	83818	1312358	83818
Aldosterone	irbesartan	3	3	false	none	Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  		1312358	83818	1312358	83818
Aldosterone	irbesartan	3	3	false	none	Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  		1312358	83818	1312358	83818
Aldosterone	irbesartan	3	5	false	none	Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  There is also an AT2 receptor in many tissues, but it is not involved in cardiovascular homeostasis.  Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor, and no agonist activity.  		1312358	83818	1312358	83818
Aldosterone	irbesartan	3	5	false	none	Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor.  There is also an AT2 receptor in many tissues, but it is not involved in cardiovascular homeostasis.  Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor, and no agonist activity.  		1312358	83818	1312358	83818
Aldosterone	irbesartan	12	14	false	none	The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  The mechanism of the antihypertensive effect of thiazides is not fully understood.  12.2 Pharmacodynamics    Irbesartan    In healthy subjects, single oral irbesartan doses of up to 300 mg produced dose-dependent inhibition of the pressor effect of angiotensin II infusions.  		1312358	83818	1312358	83818
Aldosterone	irbesartan	12	14	false	none	The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  The mechanism of the antihypertensive effect of thiazides is not fully understood.  12.2 Pharmacodynamics    Irbesartan    In healthy subjects, single oral irbesartan doses of up to 300 mg produced dose-dependent inhibition of the pressor effect of angiotensin II infusions.  		1312358	83818	1312358	83818
Aldosterone	cholesterol	17	19	false	none	Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction.  In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations.  		1312358	2438	1312358	D002784
Aldosterone	cholesterol	17	19	false	none	Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction.  In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations.  		1312358	2438	1312358	D002784
prothrombin	thiazide	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	none	none	none
prothrombin	thiazide	67	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	none	none	none
prothrombin	thiazide	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	none	none	none
prothrombin	digoxin	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	none	none	none
prothrombin	hydrochlorothiazide	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	5487	none	D006852
prothrombin	hydrochlorothiazide	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	5487	none	D006852
prothrombin	hydrochlorothiazide	67	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	5487	none	D006852
prothrombin	hydrochlorothiazide	67	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	5487	none	D006852
prothrombin	hydrochlorothiazide	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	5487	none	D006852
prothrombin	hydrochlorothiazide	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	5487	none	D006852
prothrombin	irbesartan	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	83818	none	83818
prothrombin	irbesartan	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	83818	none	83818
prothrombin	irbesartan	67	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	83818	none	83818
prothrombin	irbesartan	67	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	83818	none	83818
prothrombin	irbesartan	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	83818	none	83818
prothrombin	irbesartan	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	83818	none	83818
prothrombin	p450	67	66	false	none	Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	none	none	none
thiazide	digoxin	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	none	none	none
thiazide	digoxin	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	none	none	none
thiazide	digoxin	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	none	none	none
thiazide	digoxin	62	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	none	none	none
thiazide	hydrochlorothiazide	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	49	49	false	none	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	49	49	false	none	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	49	48	false	none	Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	49	48	false	none	Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	48	49	false	none	Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	48	49	false	none	Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	48	48	false	none	Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	48	48	false	none	Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	21	21	true	positive	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	21	21	true	positive	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	65	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	65	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	67	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	67	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	9	9	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	9	9	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	9	11	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	9	11	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	40	40	false	none	Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	40	40	false	none	Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	10	9	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	10	9	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	10	11	false	none	Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	10	11	false	none	Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	11	9	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	11	9	false	none	Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	11	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	11	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	62	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	62	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	13	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  The mechanism of the antihypertensive effect of thiazides is not fully understood.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	13	11	false	none	Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.  The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.  The mechanism of the antihypertensive effect of thiazides is not fully understood.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	30	30	false	none	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  		none	5487	none	D006852
thiazide	hydrochlorothiazide	30	30	false	none	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  		none	5487	none	D006852
thiazide	irbesartan	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	83818	none	83818
thiazide	irbesartan	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	83818	none	83818
thiazide	irbesartan	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	83818	none	83818
thiazide	irbesartan	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	83818	none	83818
thiazide	irbesartan	49	47	false	none	Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		none	83818	none	83818
thiazide	irbesartan	49	47	false	none	Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		none	83818	none	83818
thiazide	irbesartan	49	51	true	positive	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  Gender    No gender-related differences in pharmacokinetics were observed in healthy elderly (age 65 to 80 years) or in healthy young (age 18 to 40 years) subjects.  In studies of hypertensive patients, there was no gender difference in half-life or accumulation, but somewhat higher plasma concentrations of irbesartan were observed in females (11% to 44%).  		none	83818	none	83818
thiazide	irbesartan	49	51	true	positive	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  Gender    No gender-related differences in pharmacokinetics were observed in healthy elderly (age 65 to 80 years) or in healthy young (age 18 to 40 years) subjects.  In studies of hypertensive patients, there was no gender difference in half-life or accumulation, but somewhat higher plasma concentrations of irbesartan were observed in females (11% to 44%).  		none	83818	none	83818
thiazide	irbesartan	49	49	false	none	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		none	83818	none	83818
thiazide	irbesartan	49	49	false	none	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		none	83818	none	83818
thiazide	irbesartan	48	46	false	none	Studies in animals indicate that radiolabeled irbesartan weakly crosses the blood-brain barrier and placenta.  Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		none	83818	none	83818
thiazide	irbesartan	48	46	false	none	Studies in animals indicate that radiolabeled irbesartan weakly crosses the blood-brain barrier and placenta.  Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		none	83818	none	83818
thiazide	irbesartan	48	47	false	none	Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		none	83818	none	83818
thiazide	irbesartan	48	47	false	none	Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		none	83818	none	83818
thiazide	irbesartan	48	49	false	none	Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		none	83818	none	83818
thiazide	irbesartan	48	49	false	none	Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		none	83818	none	83818
thiazide	irbesartan	21	23	false	none	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  12.3 Pharmacokinetics    Irbesartan    Irbesartan is an orally active agent that does not require biotransformation into an active form.  The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.  		none	83818	none	83818
thiazide	irbesartan	21	23	false	none	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  12.3 Pharmacokinetics    Irbesartan    Irbesartan is an orally active agent that does not require biotransformation into an active form.  The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.  		none	83818	none	83818
thiazide	irbesartan	21	22	true	positive	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  12.3 Pharmacokinetics    Irbesartan    Irbesartan is an orally active agent that does not require biotransformation into an active form.  		none	83818	none	83818
thiazide	irbesartan	21	22	true	positive	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  12.3 Pharmacokinetics    Irbesartan    Irbesartan is an orally active agent that does not require biotransformation into an active form.  		none	83818	none	83818
thiazide	irbesartan	65	64	false	none	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
thiazide	irbesartan	65	64	false	none	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
thiazide	irbesartan	65	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
thiazide	irbesartan	65	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
thiazide	irbesartan	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	83818	none	83818
thiazide	irbesartan	65	67	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	83818	none	83818
thiazide	irbesartan	65	63	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
thiazide	irbesartan	65	63	false	none	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		none	83818	none	83818
thiazide	irbesartan	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	83818	none	83818
thiazide	irbesartan	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	83818	none	83818
thiazide	irbesartan	67	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	83818	none	83818
thiazide	irbesartan	67	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	83818	none	83818
thiazide	irbesartan	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	83818	none	83818
thiazide	irbesartan	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	83818	none	83818
thiazide	irbesartan	9	7	false	none	Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis.  Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		none	83818	none	83818
thiazide	irbesartan	9	7	false	none	Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis.  Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		none	83818	none	83818
thiazide	irbesartan	9	8	false	none	Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		none	83818	none	83818
thiazide	irbesartan	9	8	false	none	Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		none	83818	none	83818
thiazide	irbesartan	40	38	true	negative	Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1).  There was no induction or inhibition of 3A4.  Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  		none	83818	none	83818
thiazide	irbesartan	40	38	true	negative	Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1).  There was no induction or inhibition of 3A4.  Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  		none	83818	none	83818
thiazide	irbesartan	40	42	false	none	Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  At least 61% of the oral dose is eliminated unchanged within 24 hours.  Distribution    Irbesartan    Irbesartan is 90% bound to serum proteins (primarily albumin and 1-acid glycoprotein) with negligible binding to cellular components of blood.  		none	83818	none	83818
thiazide	irbesartan	40	42	false	none	Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  At least 61% of the oral dose is eliminated unchanged within 24 hours.  Distribution    Irbesartan    Irbesartan is 90% bound to serum proteins (primarily albumin and 1-acid glycoprotein) with negligible binding to cellular components of blood.  		none	83818	none	83818
thiazide	irbesartan	10	8	false	none	Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  		none	83818	none	83818
thiazide	irbesartan	10	8	false	none	Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.  		none	83818	none	83818
thiazide	irbesartan	62	64	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	83818	none	83818
thiazide	irbesartan	62	64	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	83818	none	83818
thiazide	irbesartan	62	63	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	83818	none	83818
thiazide	irbesartan	62	63	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	83818	none	83818
thiazide	irbesartan	62	60	false	none	Hepatic Insufficiency    The pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver.  No dosage adjustment is necessary in patients with hepatic insufficiency.  Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	83818	none	83818
thiazide	irbesartan	62	60	false	none	Hepatic Insufficiency    The pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver.  No dosage adjustment is necessary in patients with hepatic insufficiency.  Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	83818	none	83818
thiazide	irbesartan	13	14	false	none	The mechanism of the antihypertensive effect of thiazides is not fully understood.  12.2 Pharmacodynamics    Irbesartan    In healthy subjects, single oral irbesartan doses of up to 300 mg produced dose-dependent inhibition of the pressor effect of angiotensin II infusions.  		none	83818	none	83818
thiazide	irbesartan	13	14	false	none	The mechanism of the antihypertensive effect of thiazides is not fully understood.  12.2 Pharmacodynamics    Irbesartan    In healthy subjects, single oral irbesartan doses of up to 300 mg produced dose-dependent inhibition of the pressor effect of angiotensin II infusions.  		none	83818	none	83818
thiazide	irbesartan	30	29	true	positive	Limited accumulation of irbesartan (<20%) is observed in plasma upon repeated once-daily dosing.  Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  		none	83818	none	83818
thiazide	irbesartan	30	29	true	positive	Limited accumulation of irbesartan (<20%) is observed in plasma upon repeated once-daily dosing.  Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  		none	83818	none	83818
thiazide	irbesartan	30	31	false	none	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		none	83818	none	83818
thiazide	irbesartan	30	31	false	none	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		none	83818	none	83818
thiazide	irbesartan	30	32	true	positive	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  		none	83818	none	83818
thiazide	irbesartan	30	32	true	positive	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  		none	83818	none	83818
thiazide	glucuronide	30	31	false	none	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		none	none	none	none
thiazide	cholesterol	21	19	true	negative	In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations.  There was no effect on serum uric acid during chronic oral administration and no uricosuric effect.  Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  		none	2438	none	D002784
thiazide	cholesterol	21	19	true	negative	In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations.  There was no effect on serum uric acid during chronic oral administration and no uricosuric effect.  Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  		none	2438	none	D002784
thiazide	p450	68	66	false	none	Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	none	none	none
thiazide	p450	65	66	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  		none	none	none	none
thiazide	p450	67	66	false	none	Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	none	none	none
digoxin	hydrochlorothiazide	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	5487	none	D006852
digoxin	hydrochlorothiazide	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	5487	none	D006852
digoxin	hydrochlorothiazide	67	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	5487	none	D006852
digoxin	hydrochlorothiazide	67	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	5487	none	D006852
digoxin	hydrochlorothiazide	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	5487	none	D006852
digoxin	hydrochlorothiazide	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	5487	none	D006852
digoxin	hydrochlorothiazide	62	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	5487	none	D006852
digoxin	hydrochlorothiazide	62	62	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	5487	none	D006852
digoxin	irbesartan	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	83818	none	83818
digoxin	irbesartan	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		none	83818	none	83818
digoxin	irbesartan	67	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	83818	none	83818
digoxin	irbesartan	67	65	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	83818	none	83818
digoxin	irbesartan	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	83818	none	83818
digoxin	irbesartan	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	83818	none	83818
digoxin	irbesartan	62	64	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	83818	none	83818
digoxin	irbesartan	62	64	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		none	83818	none	83818
digoxin	irbesartan	62	63	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	83818	none	83818
digoxin	irbesartan	62	63	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		none	83818	none	83818
digoxin	irbesartan	62	60	true	negative	Hepatic Insufficiency    The pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver.  No dosage adjustment is necessary in patients with hepatic insufficiency.  Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	83818	none	83818
digoxin	irbesartan	62	60	true	negative	Hepatic Insufficiency    The pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver.  No dosage adjustment is necessary in patients with hepatic insufficiency.  Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		none	83818	none	83818
digoxin	p450	67	66	false	none	Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		none	none	none	none
hydrochlorothiazide	irbesartan	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	68	68	false	none	The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	68	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	49	47	false	none	Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	49	47	false	none	Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	49	51	true	positive	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  Gender    No gender-related differences in pharmacokinetics were observed in healthy elderly (age 65 to 80 years) or in healthy young (age 18 to 40 years) subjects.  In studies of hypertensive patients, there was no gender difference in half-life or accumulation, but somewhat higher plasma concentrations of irbesartan were observed in females (11% to 44%).  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	49	51	true	positive	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  Gender    No gender-related differences in pharmacokinetics were observed in healthy elderly (age 65 to 80 years) or in healthy young (age 18 to 40 years) subjects.  In studies of hypertensive patients, there was no gender difference in half-life or accumulation, but somewhat higher plasma concentrations of irbesartan were observed in females (11% to 44%).  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	49	49	false	none	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	49	49	false	none	Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	48	46	false	none	Studies in animals indicate that radiolabeled irbesartan weakly crosses the blood-brain barrier and placenta.  Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	48	46	false	none	Studies in animals indicate that radiolabeled irbesartan weakly crosses the blood-brain barrier and placenta.  Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	48	47	false	none	Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	48	47	false	none	Irbesartan is excreted in the milk of lactating rats.  Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	48	49	false	none	Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	48	49	false	none	Hydrochlorothiazide    Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.  Pediatric    Irbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients <18 years of age.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	21	23	false	none	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  12.3 Pharmacokinetics    Irbesartan    Irbesartan is an orally active agent that does not require biotransformation into an active form.  The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	21	23	false	none	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  12.3 Pharmacokinetics    Irbesartan    Irbesartan is an orally active agent that does not require biotransformation into an active form.  The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	21	22	true	positive	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  12.3 Pharmacokinetics    Irbesartan    Irbesartan is an orally active agent that does not require biotransformation into an active form.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	21	22	true	positive	Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  12.3 Pharmacokinetics    Irbesartan    Irbesartan is an orally active agent that does not require biotransformation into an active form.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	65	64	true	negative	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	65	64	true	negative	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	65	65	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	65	65	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	65	67	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	65	67	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	65	63	true	negative	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	65	63	true	negative	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	67	68	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	67	65	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	67	65	true	negative	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	67	67	false	none	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	9	7	false	none	Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis.  Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	9	7	false	none	Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis.  Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	9	8	false	none	Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	9	8	false	none	Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.  Hydrochlorothiazide    Hydrochlorothiazide is a thiazide diuretic.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	40	38	true	negative	Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1).  There was no induction or inhibition of 3A4.  Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	40	38	true	negative	Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1).  There was no induction or inhibition of 3A4.  Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	40	42	false	none	Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  At least 61% of the oral dose is eliminated unchanged within 24 hours.  Distribution    Irbesartan    Irbesartan is 90% bound to serum proteins (primarily albumin and 1-acid glycoprotein) with negligible binding to cellular components of blood.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	40	42	false	none	Hydrochlorothiazide    Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.  At least 61% of the oral dose is eliminated unchanged within 24 hours.  Distribution    Irbesartan    Irbesartan is 90% bound to serum proteins (primarily albumin and 1-acid glycoprotein) with negligible binding to cellular components of blood.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	62	64	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	62	64	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	62	63	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	62	63	false	none	Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	62	60	true	negative	Hepatic Insufficiency    The pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver.  No dosage adjustment is necessary in patients with hepatic insufficiency.  Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	62	60	true	negative	Hepatic Insufficiency    The pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver.  No dosage adjustment is necessary in patients with hepatic insufficiency.  Drug-Drug Interactions    No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	30	29	true	positive	Limited accumulation of irbesartan (<20%) is observed in plasma upon repeated once-daily dosing.  Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	30	29	true	positive	Limited accumulation of irbesartan (<20%) is observed in plasma upon repeated once-daily dosing.  Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	30	31	false	none	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	30	31	false	none	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	30	32	true	positive	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  		5487	83818	D006852	83818
hydrochlorothiazide	irbesartan	30	32	true	positive	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  		5487	83818	D006852	83818
hydrochlorothiazide	glucuronide	30	31	false	none	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		5487	none	D006852	none
hydrochlorothiazide	glucuronide	30	31	false	none	Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		5487	none	D006852	none
hydrochlorothiazide	cholesterol	21	19	true	negative	In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations.  There was no effect on serum uric acid during chronic oral administration and no uricosuric effect.  Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  		5487	2438	D006852	D002784
hydrochlorothiazide	cholesterol	21	19	true	negative	In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations.  There was no effect on serum uric acid during chronic oral administration and no uricosuric effect.  Hydrochlorothiazide    After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.  		5487	2438	D006852	D002784
hydrochlorothiazide	p450	68	66	false	none	Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	none	D006852	none
hydrochlorothiazide	p450	68	66	false	none	Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		5487	none	D006852	none
hydrochlorothiazide	p450	65	66	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  		5487	none	D006852	none
hydrochlorothiazide	p450	65	66	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  		5487	none	D006852	none
hydrochlorothiazide	p450	67	66	false	none	Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	none	D006852	none
hydrochlorothiazide	p450	67	66	false	none	Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		5487	none	D006852	none
irbesartan	glucuronide	29	31	false	none	Limited accumulation of irbesartan (<20%) is observed in plasma upon repeated once-daily dosing.  Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		83818	none	83818	none
irbesartan	glucuronide	29	31	false	none	Limited accumulation of irbesartan (<20%) is observed in plasma upon repeated once-daily dosing.  Hydrochlorothiazide    When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.  Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		83818	none	83818	none
irbesartan	glucuronide	31	33	false	none	Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%).  		83818	none	83818	none
irbesartan	glucuronide	31	33	false	none	Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%).  		83818	none	83818	none
irbesartan	glucuronide	31	31	false	none	Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		83818	none	83818	none
irbesartan	glucuronide	31	31	false	none	Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  		83818	none	83818	none
irbesartan	glucuronide	34	33	false	none	The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%).  The remaining oxidative metabolites do not add appreciably to irbesartans pharmacologic activity.  		83818	none	83818	none
irbesartan	glucuronide	34	33	false	none	The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%).  The remaining oxidative metabolites do not add appreciably to irbesartans pharmacologic activity.  		83818	none	83818	none
irbesartan	glucuronide	34	36	false	none	The remaining oxidative metabolites do not add appreciably to irbesartans pharmacologic activity.  Irbesartan and its metabolites are excreted by both biliary and renal routes.  Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  		83818	none	83818	none
irbesartan	glucuronide	34	36	false	none	The remaining oxidative metabolites do not add appreciably to irbesartans pharmacologic activity.  Irbesartan and its metabolites are excreted by both biliary and renal routes.  Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  		83818	none	83818	none
irbesartan	glucuronide	35	33	false	none	The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%).  The remaining oxidative metabolites do not add appreciably to irbesartans pharmacologic activity.  Irbesartan and its metabolites are excreted by both biliary and renal routes.  		83818	none	83818	none
irbesartan	glucuronide	35	33	false	none	The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%).  The remaining oxidative metabolites do not add appreciably to irbesartans pharmacologic activity.  Irbesartan and its metabolites are excreted by both biliary and renal routes.  		83818	none	83818	none
irbesartan	glucuronide	35	36	true	positive	Irbesartan and its metabolites are excreted by both biliary and renal routes.  Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  		83818	none	83818	none
irbesartan	glucuronide	35	36	true	positive	Irbesartan and its metabolites are excreted by both biliary and renal routes.  Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  		83818	none	83818	none
irbesartan	glucuronide	32	33	true	positive	Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%).  		83818	none	83818	none
irbesartan	glucuronide	32	33	true	positive	Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%).  		83818	none	83818	none
irbesartan	glucuronide	32	31	true	positive	Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  		83818	none	83818	none
irbesartan	glucuronide	32	31	true	positive	Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  		83818	none	83818	none
irbesartan	glucuronide	33	33	false	none	The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%).  		83818	none	83818	none
irbesartan	glucuronide	33	33	false	none	The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%).  		83818	none	83818	none
irbesartan	glucuronide	33	31	false	none	Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%).  		83818	none	83818	none
irbesartan	glucuronide	33	31	false	none	Metabolism and Elimination    Irbesartan    Irbesartan is metabolized via glucuronide conjugation and oxidation.  Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan.  The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%).  		83818	none	83818	none
irbesartan	glucuronide	38	36	true	positive	Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1).  		83818	none	83818	none
irbesartan	glucuronide	38	36	true	positive	Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1).  		83818	none	83818	none
irbesartan	glucuronide	36	36	true	positive	Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  		83818	none	83818	none
irbesartan	glucuronide	36	36	true	positive	Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  		83818	none	83818	none
irbesartan	glucuronide	37	36	true	positive	Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  		83818	none	83818	none
irbesartan	glucuronide	37	36	true	positive	Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  		83818	none	83818	none
irbesartan	cholesterol	17	19	false	none	Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction.  In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations.  		83818	2438	83818	D002784
irbesartan	cholesterol	17	19	false	none	Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses.  In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction.  In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations.  		83818	2438	83818	D002784
irbesartan	cholesterol	18	19	false	none	In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction.  In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations.  		83818	2438	83818	D002784
irbesartan	cholesterol	18	19	false	none	In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction.  In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations.  		83818	2438	83818	D002784
irbesartan	p450	68	66	false	none	Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		83818	none	83818	none
irbesartan	p450	68	66	false	none	Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.  		83818	none	83818	none
irbesartan	p450	64	66	false	none	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  		83818	none	83818	none
irbesartan	p450	64	66	false	none	However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.  Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  		83818	none	83818	none
irbesartan	p450	65	66	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  		83818	none	83818	none
irbesartan	p450	65	66	false	none	Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.  Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  		83818	none	83818	none
irbesartan	p450	67	66	false	none	Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	none	83818	none
irbesartan	p450	67	66	false	none	Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.  In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.  		83818	none	83818	none
irbesartan	p450	35	37	true	positive	Irbesartan and its metabolites are excreted by both biliary and renal routes.  Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  		83818	none	83818	none
irbesartan	p450	35	37	true	positive	Irbesartan and its metabolites are excreted by both biliary and renal routes.  Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  		83818	none	83818	none
irbesartan	p450	38	37	true	positive	In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1).  		83818	none	83818	none
irbesartan	p450	38	37	true	positive	In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1).  		83818	none	83818	none
irbesartan	p450	36	37	true	positive	Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  		83818	none	83818	none
irbesartan	p450	36	37	true	positive	Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  		83818	none	83818	none
irbesartan	p450	37	37	false	none	In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  		83818	none	83818	none
irbesartan	p450	37	37	false	none	In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  		83818	none	83818	none
glucuronide	p450	36	37	true	positive	Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide.  In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.  		none	none	none	none
